Business
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a
About this update from Tiziana Life Sciences Ltd
[{"type":"text","content":"There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severityIntranasal foralumab could represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced ICH was presented at the Annual American Academy of Neurology conference. The full presentation can be viewed at https://www.aan.com/MSA/Public/Events/AbstractDetails/52974 until May 14, 2023. Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, stated, “Intracerebral hemorrhages are the deadliest form of acute stroke with early mortality ranging from 30% to 40%. It has been well demonstrated that microglial activation and edema play a critical role in the morbidity and mortality of this devastating event.” Saef Izzy, M.D., MBCHB., Neurocritical Care faculty at Brigham and Women’s Hospital and Assistant Professor of Neurology at Harvard Medical School and presenter of the study at AAN, commented, “Currently, there are no effective interventions for ICH. Our research studied the effect of an intranasal anti-CD3 antibody in a mouse model of induced ICH. I believe that intranasal anti-CD3 represents a novel therapeutic approach for treating ICH as well as potentially other types of acute brain injury.” Specifically, the study demonstrated that intranasal anti-CD3 antibody:1 Reduced ICH injury severityImproved motor coordination recoveryImproved memory retention and functional recoveryAccelerated hematoma resolution at 7 days after ICHReduced neuronal cell death at 7 days after ICHReduced BBB leakage at 3 days after ICHReduced microgliosis at 7 days after ICHReduced astrocytosis at 7 days after ICHIncreased CD4+FoxP3+ and FoxP3+ IL...